Summary & Overview
CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcript Testing
CPT code 0016U designates a proprietary molecular diagnostic assay for detection and characterization of BCR–ABL1 major and minor breakpoint fusion transcripts performed by the University of Iowa, Department of Pathology or Asuragen on whole blood or bone marrow aspiration specimens. This PLA code matters nationally because BCR–ABL1 testing directly informs diagnosis, treatment selection, and monitoring for patients with BCR–ABL1–positive leukemias, where molecular results impact targeted therapy decisions and disease surveillance.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical and laboratory context, payer coverage considerations, common billing modifiers, and the typical service setting. The publication outlines benchmark elements and policy-relevant details that affect national coverage and billing for proprietary laboratory assays, including how PLA codes like 0016U are used to represent manufacturer- or lab-specific tests. The content highlights operational implications for laboratories and billing teams, and provides clarity on where this code fits within molecular diagnostic service lines.
This summary is intended for a national audience of clinicians, laboratory directors, and revenue cycle professionals seeking a clear, policy-oriented briefing on CPT code 0016U.
Billing Code Overview
CPT code 0016U is a Proprietary Laboratory Analyses (PLA) code describing BCR–ABL1 major and minor breakpoint fusion transcript testing performed by the University of Iowa, Department of Pathology or Asuragen on whole blood or bone marrow aspiration specimens. The test identifies and characterizes BCR–ABL1 fusion transcript variants (major and minor breakpoints) used in the molecular diagnosis and monitoring of BCR–ABL1–positive hematologic neoplasms.
Service type: Proprietary molecular diagnostic laboratory test
Typical site of service: Clinical laboratory or hospital laboratory
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with newly diagnosed chronic myeloid leukemia (CML) presents for initial molecular baseline testing and later for routine disease monitoring. Peripheral whole blood or bone marrow aspiration is collected and sent to a reference laboratory (University of Iowa Department of Pathology or Asuragen) for BCR–ABL1 major (p210) and minor (p190) breakpoint fusion transcript quantification using a validated laboratory-developed test described by PLA code 0016U. The clinical workflow includes: ordering the test in the electronic medical record, obtaining informed consent for laboratory testing as required by the facility, phlebotomy or bone marrow aspiration by oncology or hematology staff, specimen packaging and shipment to the performing lab, and receipt of a quantitative molecular report used by the treating hematologist/oncologist to guide diagnosis, initial therapy selection, and ongoing response assessment (to assess molecular response, minimal residual disease, or possible relapse). Typical sites of service are hospital inpatient, hospital outpatient infusion or oncology clinic, and reference laboratory processing. Common clinical indications include initial confirmation of BCR–ABL1 transcript presence at diagnosis, baseline quantification before tyrosine kinase inhibitor therapy, periodic monitoring for major molecular response, and evaluation of rising transcript levels suggesting loss of response or resistance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |